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ABSTRACT: In order to improve the eﬃcacy and safety of treatments, drug dosage
needs to be adjusted to the actual needs of each patient in a truly personalized medicine
approach. Key for widespread dosage adjustment is the availability of point-of-care
devices able to measure plasma drug concentration in a simple, automated, and cost-
eﬀective fashion. In the present work, we introduce and test a portable, palm-sized
transmission-localized surface plasmon resonance (T-LSPR) setup, comprised of oﬀ-
the-shelf components and coupled with DNA-based aptamers speciﬁc to the antibiotic
tobramycin (467 Da). The core of the T-LSPR setup are aptamer-functionalized gold
nanoislands (NIs) deposited on a glass slide covered with ﬂuorine-doped tin oxide
(FTO), which acts as a biosensor. The gold NIs exhibit localized plasmon resonance in
the visible range matching the sensitivity of the complementary metal oxide
semiconductor (CMOS) image sensor employed as a light detector. The combination
of gold NIs on the FTO substrate, causing NIs size and pattern irregularity, might
reduce the overall sensitivity but confers extremely high stability in high-ionic solutions, allowing it to withstand numerous
regeneration cycles without sensing losses. With this rather simple T-LSPR setup, we show real-time label-free detection of
tobramycin in buﬀer, measuring concentrations down to 0.5 μM. We determined an aﬃnity constant of the aptamer−tobramycin
pair consistent with the value obtained using a commercial propagating-wave based SPR. Moreover, our label-free system can
detect tobramycin in ﬁltered undiluted blood serum, measuring concentrations down to 10 μM with a theoretical detection limit
of 3.4 μM. While the association signal of tobramycin onto the aptamer is masked by the serum injection, the quantiﬁcation of
the captured tobramycin is possible during the dissociation phase and leads to a linear calibration curve for the concentrations
over the tested range (10−80 μM). The plasmon shift following surface binding is calculated in terms of both plasmon peak
location and hue, with the latter allowing faster data elaboration and real-time display of the results. The presented T-LSPR
system shows for the ﬁrst time label-free direct detection and quantiﬁcation of a small molecule in the complex matrix of ﬁltered
undiluted blood serum. Its uncomplicated construction and compact size, together with the remarkable performances, represent a
leap forward toward eﬀective point-of-care devices for therapeutic drug concentration monitoring.
Tailoring drug treatments for each patient in a personalizedmedicine approach holds the promise of dramatically
improving therapeutic outcomes and safety. At present, for a
vast majority of human medicines, a standard initial dosage is
still deﬁned on the basis of population studies and applied
uniformly to the patients. However, certain drugs demonstrate
remarkably large interindividual variability in their absorption
and disposition rates (i.e., their pharmacokinetic character-
istics). This leaves a large part of the patients with under- or
overexposure in terms of circulating drug concentrations, thus
possibly resulting in ineﬃcacy or adverse eﬀects, respectively. In
the absence of an early, predictive, easily monitored biomarker,
treatment failure or toxicity must become clinically manifested
to trigger dosage adaptation. Circulating drug concentration
represents a suitable surrogate marker for treatment monitoring
and readjustment in such situations. It is available for a limited
number of drugs hitherto, and it relies on distant central
laboratories equipped with large, costly apparatus. Therefore,
there is an important need for miniaturized and aﬀordable
systems that could simplify the quantiﬁcation of drugs in the
patient’s blood, allowing the blood analysis to be completed at
the medical doctor’s oﬃce. Most of the current drugs are small
molecules (m.w. < 1000 Da) circulating at or below micromolar
concentrations. These molecules are chemically stable and
often devoid of reactive moieties available for labeling, which
makes them diﬃcult to detect and quantify. Their determi-
nation in biological ﬂuids through a point-of-care (POC)
system thus represents a deﬁnite challenge.
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Among other techniques, surface plasmon resonance (SPR)
has gained importance in the last decades as real time and label-
free surface technique for molecular detection.1−4 The SPR
phenomenon occurs when light with a particular wavelength is
shone at the interface between a thin layer of conductive metal
(often gold) and a dielectric, yielding an evanescent plasmon
wave that is highly sensitive to the refractive index (RI) in the
surroundings of the interface.5,6 When the metal surface is
functionalized with a ligand, analyte binding causes a local
increase of the RI that can be followed and directly measured
by a red-shift of the SPR.7 Direct detection of small molecules
by SPR can be challenging, since their small mass causes only
minor RI changes on the surface, which are diﬃcult to detect.
Nevertheless, Chang and coauthors recently demonstrated the
direct measurement of several small molecules with a
commercial propagating SPR system and DNA aptamers,8
with detected concentrations varying between a few μM and
tens of nM. This shows that, albeit in buﬀer solution, it is
possible to detect small molecules in a label-free setting via
propagating SPR.
In order to measure drug concentration in patient samples,
however, SPR detection must take place in more complex
matrices than buﬀers. SPR measurement of a cardiac biomarker
(brain natriuretic peptide, BNP) in undiluted blood serum was
shown in a commercial SPR system using DNA aptamers on
the chip surface, and nanoparticles (NP) coated with antibodies
(Ab) to generate and enhance the signal.9 The relatively high
molecular weight of BNP (>3 kDa) and the complex labeling
system allow the authors to attain a limit of detection (LOD) in
the range of aM. Going toward a portable commercial SPR
setup, another work shows the detection of a small molecule
(cortisol) in the complex matrix of human saliva.10 Once again,
in order to increase the signal generated from the small
molecule, a competitive assay with a monoclonal antibody (Ab)
was used. Interestingly, an in-line ﬁltering system was
introduced in order to reduce the matrix complexity, therefore
strongly decreasing the amount of large molecules that could
reach the SPR surface. Although it is possible to scale it down,
the propagating SPR systems described above often require
complex optics and scanners diﬃcult to miniaturize.
Another SPR approach, called localized-SPR (LSPR)
employs a disconnected pattern of thin metal to generate a
nonpropagating plasmon.11−15 In the transmission conﬁgu-
ration (T-LSPR), the LSPR, excited by the passing-through
light, can be readily characterized from the transmitted light,
thus greatly simplifying the detection system.16−18 Due to its
nonpropagating nature, LSPR is also prone to dramatically
increase throughput, allowing simultaneous measurements of
multiple analytes.19 A recent work shows the LSPR detection of
a small molecule (ATP) through a simple system that promises
high throughput and can be further miniaturized.20 However,
the detection is only tested in buﬀer, and it is further
complicated by the use of two types of NPs, of which one is
modiﬁed with the speciﬁc aptamer and the other with a
complementary short ssDNA. Acímovic ́ and colleagues moved
a step forward by measuring several biomarkers in 50% blood
serum via a high throughput LSPR21 in both direct and
sandwich assays. Nevertheless, the cancer-speciﬁc biomarkers
analyzed (alpha-feto-protein and prostate speciﬁc antigen) have
a molecular mass between 34 and 70 kDa and are therefore not
small molecules.
In this paper, we show for the ﬁrst time direct detection and
measurement of a small molecule (tobramycin, molecular
weight of 467 Da) in undiluted blood serum via a simple
transmission LSPR system. The T-LSPR setup is based on gold
nanoislands (NIs) self-assembled on a glass slide covered with a
ﬂuorine-doped tin oxide (FTO) layer. This T-LSPR has a very
simple, compact, and cost-eﬀective construction while retaining
the capability of an increased throughput by using a
complementary metal oxide semiconductor (CMOS) image
sensor as a light detector. In parallel to the T-LSPR setup, two
algorithms to extract the SPR information were also developed
and tested in this work. The T-LSPR system gives excellent
results in buﬀer and, in undiluted blood serum, is almost able to
attain the minimal analytical concentration currently required
in the clinics.
■ EXPERIMENTAL SECTION
Microﬂuidic Plasmonic Chip for Molecular Analytics.
The microﬂuidic chip is composed of a glass slide coated with
gold nanostructures and a microﬂuidic module which consists
of two independent channels. Gold nanoislands (NIs) are
formed on ﬂuorine-doped tin oxide (FTO)-coated glass (45
mm × 12 mm × 2 mm) by direct thermal evaporation and
subsequent thermal annealing. The obtained nanostructures
exhibit plasmonic resonance in the visible range (570 nm) and
are extremely stable under ﬂow conditions, due to the fact that
gold penetrates into the FTO layer during the thermal
annealing step.22 A detailed description of the NIs formation
process can be found in previous works.23,24
Microﬂuidic channels for the delivery of solutions to the NIs
surface are obtained by sticking on the top of the FTO-glass
slide a PMMA cover plate: the intermediate stick layer is a
made out of double coated tape (3 M High Performance
Double Coated Tape 9086) on which two regions of 2 mm ×
14 mm × 150 μm have been removed by laser micromachining,
leading to two channels of identical size. Inlets and outlets are
0.8 mm in diameter such that microﬂuidics connections are
possible from standard syringe needles (Terumo) connected to
the syringe pump (Harvard Apparatus 11 Elite Nanomite
Programmable Syringe Pump) via ﬂexible silicon tubes (Sani-
Tech STHT-C).
Surface Functionalization and Sample Preparation.
The surface of the NIs is modiﬁed on diﬀerent regions of the
slide with organic layers immediately after the thermal
annealing. The formation of the layers is obtained by spotting
50 μL volume solutions and incubating at room temperature
for 16 h. The solutions deposited contain either 3 μM of the
DNA aptamer speciﬁc for tobramycin25 (SH5′-TCCGT-
GTATAGGTCGGGTCTCTTGCCAACTGATTCGTTG-
AAAAGTATAGCCCCGCAGGG-3′; Sigma) in PBS buﬀer or
1 mM of 6-mercapto-1-hexanol (MCH, Sigma) in Tris-EDTA
10:1 mM buﬀer (TE 1×) as a control spot. The spots occupy
an area of about 20 mm2.
The immobilization of the molecules is based on covalent
sulfur−gold bonds. After the incubation, the slides are rinsed
with ultrapure water and gently dried with nitrogen. The
surface is then passivated with MCH 1 mM in TE 1× for 30
min. Finally, the samples are thoroughly rinsed with ultrapure
water and dried by a nitrogen stream. Tobramycin is diluted
either in TE 1× buﬀer or in FBS (fetal bovine serum, cell
culture grade). FBS solutions (with or without tobramycin)
were subsequently ﬁltered with an Amicon Ultra Filter
(Millipore, Switzerland) with 3 kDa cutoﬀ in order to remove
most of the protein content. NaCl, PBS, and fetal bovine serum
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(FBS) were all purchased from Sigma-Aldrich, while TE buﬀer
was purchased from Applichem.
Measurement Setup. The T-LSPR setup employs a
nonpolarized white light LED as excitation source (Cree
Lamp XP-E supplied by 2.49 V) and a CMOS image sensor
(ST Microelectronics VW6558) as light detector. The light
transmitted through the NI-coated slides contains information
on the plasmonic resonance phenomenon occurring at the
NIs−solution interface. The light is collected on the CMOS
detector by a plano-convex lens (Thorlabs LA1270-A) that
reduces the focal distance between the NI-coated slide and the
CMOS sensor. Relative distances among the elements of the
optical setup are represented in in Figure 1a,b. The use of a
CMOS sensor allows one to image a large area of the slide and
to distinguish the light absorbed by the diﬀerent regions
pertaining to immobilized aptamer molecules or to control
spots bearing MCH.
The CMOS sensor is 3.5 × 3.03 × 2.5 mm3 in size. It has an
integrated lens with focal length of 1.25 mm and horizontal
ﬁeld of view (HFOV) of 60°. The resolution is 648 × 488
pixels of 2.2 μm × 2.2 μm size each, with red (R), green (G),
and blue (B) ﬁlters arranged in a Bayer pattern conﬁguration. A
diﬀusor is placed at a 10 mm distance from the LED to improve
light uniformity and to prevent hot spots on the image. All the
setup components are placed inside a 3D printed case of 5.5 cm
× 6 cm × 8.5 cm in size which is developed in a dark material
to reduce internal reﬂections (Figure 1c).
Data Analysis. Images of 200 × 300 pixels were recorded at
8 frames per second with an analog gain set to 1; they were
saved in a sequential order in bitmap format and ﬁnally were
displayed in real-time on the screen. Regions of interest (ROIs)
of about 800 pixels were manually selected on the images in
order to include the previously spotted areas (Figure 2, red
rectangles). RGB intensities were then averaged for each ROI
yielding to the corresponding output signal used for further
data analysis. First, R, G, and B values for the light
transmittance are mediated over the ROI. Successively, the
images are analyzed to determine the resonance peak
wavelength by means of an algorithm previously developed.23
The binding of molecular species on the NIs causes a red-shift
in the plasmon peak, while the shape of the resonance itself is
only slightly aﬀected.
The characteristic shape of the plasmon resonance is
determined with a commercial spectrophotometer (Ocean
Optics USB200+) and then used as a reference by the
algorithm. At each iteration, the reference curve is shifted in
wavelength and transmittance until the best ﬁt with the set of
three measured points is reached and the peak location is
estimated. The algorithm also takes into account the spectral
characteristics of the white LED and the RGB ﬁlters used in the
optical setup (Figure 3). The detailed description of the
algorithm can be found elsewhere.23
In this work, we exploited an alternative approach to
represent the plasmonic resonance in the color space. In the
HSV (hue, saturation, value) representation of colors, the hue
(H) value corresponds to the perceived color tone and thus
indirectly to the physical wavelength; therefore, it is a suitable
parameter to evaluate the spectral variations of the plasmon
resonance peak in the spectrum. In fact, it solely depends on
the measured combination of red, green, and blue pixel values,
and it is independent from the overall luminous intensity.
Raw data are ﬁrst converted from the Bayer pattern to RGB
values and then converted into the HSV color space. For each
selected ROI, the hue of the average of the selected pixels is
calculated and then low-pass ﬁltered (ﬁlter order of 126, cutoﬀ
frequency of 0.00438 Hz).
= R G BMAX MAX( , , )
= R G Bmin min( , , )
Figure 1. Custom-made T-LSPR setup. (a) Digital rendering of the components of the T-LSPR setup. (b) Side view with relative distances
indicated. (c) Picture of the complete setup.
Figure 2. Plasmonic sensor. Schematic representation of a NIs FTO
glass slide indicating the spots on the surface and the areas exposed to
the microﬂuidic channels (right). An example of an image acquired by
the CMOS camera (left). The ROIs are selected during the data
processing. (1) Reference FTO surface. (2) Aptamer spots. (3) MCH
control spots. (4) Blank NIs.
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.5b00389
































= + <H H H1 if 0
The variation of the hue was then used to display the plasmonic
changes over time.
Stability of the NIs Layer in Aqueous Solution. Stability
of the gold NIs was tested by measuring the NIs FTO-glass
prior and after 24 h immersion in TE 1× buﬀer. Extinction
spectra measured with a commercial spectrophotometer
(Ocean Optics 2000+) show no appreciable shift. In order to
test the NIs adhesion in the presence of a ﬂow of solution, the
microﬂuidic module was mounted on the NIs FTO-glass slide
and TE buﬀer is ﬂushed for 10 min at 5 μL/min. The negligible
change of the peak location proves the stability of the gold NIs
under ﬂow.
Real-Time Monitoring of Surface Binding. Microﬂuidics
was built on top of the NIs FTO-glass slide such that two
independent channels are covering the areas spotted with the
DNA aptamer, the MCH reference spots, a bare gold NIs area,
and a blank FTO area (Figure 2). Surface conditioning,
consisting of 1 M NaCl solution followed by TE 1×, is
performed prior the experiments. Tobramycin in diﬀerent
concentrations is delivered to the sensitive areas and is followed
by TE buﬀer to observe the dissociation kinetics. NaCl (1 M) is
used as a regeneration solution to remove the remaining
tobramycin on the surface and to leave the DNA aptamers on
the surface ready for the next cycle.
■ RESULTS AND DISCUSSION
Small Molecule Analysis with a Custom-Made LSPR
System and DNA Aptamers. DNA aptamers have been
widely used for small molecule detection, also in combination
with SPR-based systems.8,9 We have previously developed a
DNA aptamer that can successfully detect the antibiotics
tobramycin (m.w. 467 Da) on propagating SPR (Biacore X100,
GE), in a label-free assay, down to 50 nM in buﬀer solution.25
We therefore deployed the same aptamer in order to observe
the signal generated by the small molecule tobramycin on a
nonconnected pattern of plasmonic gold NIs in a transmission
localized SPR conﬁguration.
The DNA aptamers were immobilized on the gold NIs via
thiol−gold covalent binding, similarly to the passivating self-
assembled monolayer of 6-mercapto-1-hexanol. During the
injection of solutions at diﬀerent tobramycin concentrations,
molecular binding to the aptamer is detected by monitoring the
RI change in the proximity of the NIs, which causes a shift of
the plasmon resonance wavelength. Surface drug binding
induces an increase of the local RI resulting in a redshift of
the plasmon peak.7,11−13,26 The real-time shift of the plasmon
peak is extracted by a custom developed algorithm (see the
Experimental Section), and it is compared with the
corresponding change in hue, which has already been used to
detect plasmonic changes related to bulk RI measurements27
(Figure 4). Despite the small molecular weight of tobramycin, a
binding/dissociation curve is clearly detectable, while the
control spot (MCH) shows no apparent binding (Figure 4,
bottom). The noise on the peak (0.0715 nm) and on the hue
(0.0001) baselines allows one to distinguish the association and
dissociation binding interactions. The two approaches for
plasmon shift quantiﬁcation show high consistency, as they
exhibit a linear correlation independent from the matrix where
the binding event takes place (TE buﬀer and serum tested,
Supporting Information). The diﬀerence in the ripples between
the hue and peak signals visible in Figure 4 is due to
dissimilarities in data treatment (e.g., noise ﬁltering) amid the
two approaches, and it is not related to diﬀerences in the signal
information content. Hue calculation only requires a quick
conversion of the RGB values, thus reducing the complexity of
the data elaboration and allowing one to plot the results in real-
time during the experiment. In addition, the hue is independent
from the light intensity; therefore, it is insensitive to the light
distribution over the CMOS image sensor. In this work, we
show for the ﬁrst time that hue can be reliably used to measure
and display real-time surface binding of small molecules in SPR.
Real-Time Sensing of Tobramycin in TE Buﬀer. In
order to conﬁrm the ability of the T-LSPR setup to quantify
tobramycin binding on the DNA aptamers, we sequentially
injected tobramycin on the sensing array at diﬀerent
concentrations (0.5, 1, 2, 5, and 10 μM), followed by
dissociation (TE buﬀer) and regeneration solution (1 M
NaCl, Figure 5). The hue variation of the DNA aptamer-
functionalized NIs (blue line) and of the control-functionalized
NIs (MCH, green line) was then followed in real-time. A signal
proportional to the amount of bound tobramycin is clearly
visible in the aptamer-functionalized spots, while the control
spot only shows a slight variation of signal probably due to
some nonspeciﬁc binding and bulk eﬀect. NaCl brings back the
baseline to the value before tobramycin injection, thus
eﬃciently removing the tobramycin bound to the surface and
Figure 3. Optical characterization of the plasmon, light source, and
light detector employed. Gold NIs spectrum (light blue line) measured
by a UV−vis-NIR spectrophotometer Jasco V-570 in transmittance
mode with a scan speed of 200 nm/min and 1 nm bandwidth. The
solid black line represents the white LED emission. The dashed blue,
green, and red lines represent the RGB ﬁlters of the CMOS image
sensor normalized by their respective maximum values, and the
continuous blue, green, and red lines are the same curves convoluted
with the LED spectrum.
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leaving the DNA aptamers available for capturing drug
molecules during the forthcoming cycle.
The eﬀective surface regeneration allows one to reuse the
same surface without requiring the functionalization of a new
NIs FTO-coated glass slide. The association and dissociation
signals for the diﬀerent concentrations of tobramycin tested
increase with the concentration (Figure 6). Injections of 0.5
μM of tobramycin show a slow association rate which is
evidently aﬀected by the limiting mass transport phenomenon,
while at higher tobramycin concentrations, the association rates
become faster. Plotting the association signal values at steady-
state with respect to the concentration of tobramycin injected
(Figure 7) allows us to ﬁt the points using the Langmuir
equation and, hence, to calculate the equilibrium dissociation
constant (KD). KD is indeed the concentration of tobramycin
needed to achieve a half-maximum binding and in our case
corresponds to 0.26 μM. The same analysis performed with a
commercial SPR gives a KD of 0.23 μM for the same aptamer.
25
The high similarity of the KD obtained with our T-LSPR and
the commercial SPR indicates that the DNA aptamers are
comparably functionalized on the surface, while retaining their
ability to recognize tobramycin. Moreover, this suggests that
the information from the T-LSPR system is analogous to that
of the commercial SPR for the tested concentrations.
Our T-LSPR system can clearly detect tobramycin at least
down to the concentration of 0.5 μM (minimum tested
concentration), while with the same aptamer on the
Figure 4. Surface detection of small molecule binding on DNA
aptamers. 70 μL of tobramycin (10 μM) in TE 1× is delivered to the
DNA aptamers (top ﬁgure) and to a control MCH (bottom ﬁgure) on
the surface at 5 μL/min. Peak location (black line) and hue (red line)
are extracted from the same RGB data collected by the CMOS image
sensor. The pink and purple areas represent the association and the
dissociation phase, respectively. The green area represents the
regeneration step performed by injection of NaCl solution. The
control spot does not show any speciﬁc response to the injection of
tobramycin.
Figure 5. Real-time association and dissociation of tobramycin
recognized by the selected DNA aptamer (blue line) attached to the
surface. 70 μL of tobramycin in concentrations of 0.5, 1, 2, 5, and 10
μM in TE 1× are delivered to the surface at 5 μL/min. The green line
represents the control measurement performed with a layer of MCH
on the NIs, which allows one to cancel out the signal of the bulk eﬀect
and to verify the occurrence of nonspeciﬁc binding. The pink and
purple areas indicate the association and dissociation phases,
respectively. The green areas correspond to the injection of NaCl as
a regeneration step.
Figure 6. Kinetics association and dissociation of tobramycin for the
diﬀerent concentrations tested.
Figure 7. Hue variation for diﬀerent concentrations of tobramycin
averaged over 3 independent DNA aptamer spots on the same NIs
FTO glass slide (empty green circles, blue squares, and red triangles)
and for the MCH control spot (red squares).
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commercial propagating SPR, we could detect at least down to
50 nM. Chang et al. showed direct assay quantiﬁcation of
several small molecules (m.w. between 75.1 and 690.4 Da) via
DNA aptamers in buﬀer with a commercial propagating SPR
system.8 Although the sensitivity obviously also depends on the
binding strength between ligand and analyte, for molecules of
comparable size to tobramycin, they report a similar limit of
detection of 0.82 μM (ATP, m.w. 506 Da) and 40 nM (ﬂavin
mononucleotide, m.w. 456 Da). Xie et al. also tested the
detection of ATP reporting a lower limit of detection of 0.01
μM in buﬀer.20 Nevertheless, the label-based approach used
takes advantage of gold nanospheres conjugated both to the
small molecule and to its DNA aptamer in order to enhance the
LSPR signal.
Overall, the custom T-LSPR presented shows data that are
comparable to the commercial propagating SPR in terms of the
measurement of binding aﬃnity. The apparent sensitivity is, at
worst, 1 order of magnitude lower than the commercial SPR,
although it remains in line with the sensitivity shown by others
for similarly small molecules in label-free assays.
Real-Time Sensing of Tobramycin in Undiluted
Serum. A POC system to analyze patient blood with fast
and precise response needs to be able to measure tobramycin
by binding with the DNA aptamer in the presence of a complex
matrix. Therefore, we tested our T-LSPR set up for tobramycin
detection in undiluted fetal bovine serum (FBS) as a surrogate
for human serum. Because our system is label-free and, thus,
prone to be sensitive to nonspeciﬁc binding, FBS was ﬁltered
with a 3 kDa cutoﬀ membrane in order to remove most of the
proteins in the serum (see Experimental Section).10
Tobramycin concentrations within the clinical analytical
range (10, 20, 40, 60, and 80 μM; clinical range of 0.5−80 μM)
were then spiked in FBS, ﬁltered, and injected at 10 μL/min
over the sensing areas in order to be measured with the T-
LSPR measurement system (Figure 8). The data were
normalized for baseline drift and response variations by the
signal corresponding to the regeneration injection (NaCl 1M,
entirely bulk eﬀect). In order to control for nonspeciﬁc binding
of molecules, as well as to evaluate serum bulk eﬀect,
tobramycin-spiked FBS injections were alternated with
injections of pure FBS. The control injections show a
pronounced bulk eﬀect because of the higher RI of serum
with respect to TE buﬀer (Figure 8). The signal of the serum
samples is constant over the multiple injections, and moreover,
it is not aﬀected by the presence of tobramycin (blue and pink
areas in Figure 8). Nevertheless, the tobramycin captured by
the DNA aptamer is visible and measurable from the start of
the dissociation phase (purple areas), when only TE buﬀer is
injected in the channels. The tobramycin-speciﬁc signal in the
early dissociation phase exhibits a sharp increase to a value
related to the amount of tobramycin injected. The control spot
(data not shown) and the injections of serum without
tobramycin (Figure 8) show no binding signal in that phase.
The reason why serum prevents the observation of the
binding of tobramycin to the DNA aptamer during the
association is still unclear. One possibility is that the serum
could partially absorb the light at the wavelength required for
plasmon excitation, hence partially reducing the plasmon
eﬃciency. However, the FBS absorbance spectrum, measured
with a commercial spectrophotometer (Nanodrop 2000c
Thermo Scientiﬁc), only shows peaks at 200 and 300 nm
(data not shown), which are out of the range for the NIs
plasmon. On the other hand, ﬁltered blood serum still contains
salts, peptides, small proteins, hormones, and further ions. As a
result, blood serum has a high load of charges, which has been
shown to be suﬃcient to modify the surface charge of particular
molecules28 and therefore might reduce the tobramycin-
induced signal. Additionally, in the context of the metal−
halides complex formation, it was shown that the interaction
between an electrolyte and a plasmonic metal surface can aﬀect
the plasmonic properties of the system.29 Therefore, an
interesting hypothesis that requires further investigation is
that the electrolytes present in the serum might be damping the
plasmon, therefore conﬁning the plasmonic electric ﬁeld to the
close proximity of the gold NIs surface. This would reduce the
plasmon penetration depth into the microﬂuidic channel, thus
restricting the sensing volume below the height of the
tobramycin binding site on the aptamer.
Averaging the dissociation signal of tobramycin on the DNA
aptamer spots (Figure 9) shows a linear trend with a sensitivity
of 0.01 (hue variation per μM). The average variability of the
two experiments over the diﬀerent concentrations has been
duplicated, summed to the average signal at 0 μM, and used to
estimate the minimum resolvable concentration of tobramycin
in serum, which corresponds to 3.4 μM.
To date, there are no directly comparable works on label-free
SPR detection of small molecules. An existing attempt was
based on nanoparticle-SPR enhancement, combined with a
sandwich assay on a conventional propagating SPR system.9
The detection of brain natriuretic peptide (BNP, 3.46 kDa) in
Figure 8. Real-time association and dissociation of tobramycin recognized by the selected DNA aptamer attached to the surface. 70 μL of
tobramycin with the concentrations of 10, 20, 40, 60, and 80 μM in undiluted serum, alternated with control injections of serum without tobramycin,
are delivered to the surface at 10 μL/min. The pink and purple areas indicate the association and dissociation phases, respectively. The green areas
correspond to the injection of NaCl as a regeneration step.
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this work was reported down to 10 aM in serum. Nevertheless,
the LOD of BNP is extremely sensitive to the concentration of
the nanoparticle-labeled antibody employed for the sandwich
assay, making this approach heavily dependent on feedback
adjustment. In another work, LSPR direct detection of IgG
(m.w. 150 kDa) in 50% serum showed a LOD of 0.4 nM.21
However, 30 min of measurement is necessary to obtain a
detectable signal, due to the competition of the analyte
molecules with the abundant serum constituents. With the
same setup, slightly smaller analytes, such as alpha-feto-protein
(m.w. 70 kDa) and prostate speciﬁc antigen (m.w. 34 kDa),
were detected by means of a sandwich assay approach.
Although low LODs were attained (7.1 and 29.4 pM,
respectively), the employment of a sandwich assay might not
be suitable for the detection of small molecules.
The presented T-LSPR system is able to quantify tobramycin
with a label-free direct assay in undiluted blood serum. The
measured concentrations of tobramycin in patients’ blood range
between 0.5 and 80 μM,30 and the minimum is less than 1
order of magnitude below the theoretical LOD reported in this
work. Interestingly, the DNA aptamer used in this work showed
excellent selectivity in propagating SPR toward molecules
belonging to the class of coadministered antibiotics (carbeni-
cillin, penicillin-like) and good selectivity against a similar
aminoglycoside antibiotic (kanamycin),25 therefore conﬁrming
its potential in clinical analysis.
The aptamer-modiﬁed NIs FTO surface was able to
withstand more than 20 h of repeated binding and regeneration
cycles. The remarkable stability of both the aptamer−NIs
bonds and the NIs patterns on the FTO well matches a critical
requirement for molecular sensing.31,32 We think that this
property arises from the porosity of the FTO layer and the
subsequent penetration of the NIs in it, as previously
suggested.22−24 The capability of our T-LSPR sensor to resolve
smaller RI changes is limited by the irregularity of the sensor
surface which broadens the plasmon and also is due to the FTO
granular structure. Nevertheless, attaining more regular shape
and patterns of the NIs would allow one to improve the
sensitivity.33−37
■ CONCLUSIONS
With the aim of improving personalized medicine through
tailored drug dosage, by allowing small drug quantiﬁcation in
patient blood at the point-of-care, we present in this work a
portable T-LSPR setup. Our system is made from oﬀ-the-shelf
components with dimensions down to a palm size. We
fabricated NIs FTO-coated glass slides functionalized with
DNA aptamers showing very high stability in solvents and in
high ionic-strength solutions. Importantly, these allowed us to
perform multiple regeneration cycles without critical degrada-
tion of the signal and to determine kinetic parameters that well
matched those obtained with a commercial propagating SPR
system.
We challenged our device in a label-free conﬁguration by
quantifying tobramycin, a low-molecular weight drug that
requires personalized dosage. Determination of tobramycin
concentrations in TE 1× buﬀer down to 0.5 μM was attained.
Tobramycin detection was also performed in ﬁltered undiluted
blood serum, showing an estimated LOD of 3.4 μM and a
linear concentration dependence of the signal.
This is the ﬁrst work reporting on a portable T-LSPR system
measuring the concentration of small molecules in ﬁltered
undiluted serum with a direct assay conﬁguration. At present,
the demonstrated detection limit diﬀers from the clinical range
by less than 1 order of magnitude. It is therefore not too
optimistic to envision that our portable T-LSPR system will be
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